- Overview
- Bayer Group
- Stock
- Debt
- Reports
- Annual Stockholders’ Meeting 2020
- Events
- Inside Information
- Latest Inside Information
- Archive Overview
- Inside Information 2019
- Inside Information 2018
- Inside Information 2017
- Ad-hoc 2016
- Ad-hoc 2015
- Ad-hoc 2014
- Ad-hoc 2013
- Ad-hoc 2012
- Ad-hoc 2011
- Ad-hoc 2010
- Ad-hoc 2009
- Ad-hoc 2008
- Ad-hoc 2007
- Ad-hoc 2006
- Ad-hoc 2005
- Ad-hoc 2004
- Ad-hoc 2003
- Ad-hoc 2002
- Ad-hoc 2001
- Ad-hoc 2000
- Ad-hoc 1999
- Ad-hoc 1998
- News
- Investor News
- Press
- Archive
- Overview
- Investor News 2019
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Handouts
- Downloads
- Service
Data for Riociguat presented at the CHEST 2012 Annual Meeting
October 20 - 25, 2012
Atlanta, Georgia, USA
Findings from two Phase III studies evaluating Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) and in pulmonary arterial hypertension (PAH) were presented in the late-breaking abstracts session on October 23, 2012 from 4:30 – 5:45 p.m. EDT at the 2012 American College of Chest Physicians (ACCP) annual meeting (CHEST 2012) in Atlanta, USA.
On this occasion we hosted a conference call for investors and analysts on October 24, 2012 at approx. 1:00 p.m. CEST (11:00 a.m. GMT).
Oktober 24, 2012: Investor Conference Call on Riociguat
with
Dr. Kemal Malik, Head of Global Development at Bayer HealthCare Pharmaceuticals
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations
MP3 audio recording (presentation and discussion)
| Transcript | Download PDF collect (131 KB) |